Johnson & Johnson got approval for its robotic surgical system. The stock went up. Retail traders saw the news and thought they discovered alpha in a healthcare conglomerate that's been around since 1886.
The system competes with Intuitive Surgical's da Vinci platform, which has owned the robot-cuts-you-open market for two decades. J&J's version does the same thing but costs slightly different money. Hospitals will buy both because administrators love spending capital budgets on machines that beep.
Every hospital CEO in America just called their procurement team to ask how fast they can lease a unit. Not because outcomes improve. Because the hospital across town ordered one last month and now there's a gap in the regional robot-per-bed ratio. This is how medical devices get sold. Fear of appearing poor to other hospitals.
The Investing Club called this "a big win" in their Homestretch update, an actionable afternoon newsletter for people who need to be told what to think about earnings before the final hour of trading. Actionable means you get to lose money with conviction instead of hesitation.
J&J also reported earnings. They sold baby powder alternatives and band-aids and whatever else fits in a CVS endcap. The earnings were fine. Everything was fine. Nothing changed except the number of robots doctors can choose from when they want to make an incision using a joystick.
Somewhere right now a day trader is googling "J&J robot moat" and adding shares in after-hours because a newsletter told him this was the inflection point. He'll sell at a loss in six weeks when the next medical device company announces their robot, which will also be a big win, which will also result in hospitals buying f*cking everything.
Photo by Leo_Visions on Unsplash
Leave a Comment